Vedana Therapeutics Raises $46M Series A Led by Westlake BioPartners and Canaan Partners for Migraine Therapy Development

Vedana Therapeutics, a Seattle-based biotech company focused on migraine prevention therapies, raised $46 million in a Series A funding round. The round was led by Westlake BioPartners and Canaan Partners, with participation from Dawn Biopharma.

VVedana Therapeutics